Effects of Metreleptin in Pediatric Patients With Lipodystrophy

Context Lipodystrophy syndromes are rare disorders of deficient adipose tissue. Metreleptin, a human analog of leptin, improved metabolic abnormalities in mixed cohorts of children and adults with lipodystrophy and low leptin. Objective Determine effects of metreleptin on diabetes, hyperlipidemia, nonalcoholic fatty liver disease (NAFLD), growth, and puberty in pediatric patients with lipodystrophy and low leptin. Design Prospective, single-arm, open-label studies with continuous enrollment since 2000. Setting National Institutes of Health, Bethesda, Maryland. Patients Fifty-three patients aged 6 months to <18 years with lipodystrophy, leptin level <8 ng/mL (male patients) or <12 ng/mL (female patients), and ≥1 metabolic abnormality (diabetes, insulin resistance, or hypertriglyceridemia). Intervention Subcutaneous metreleptin injections (0.04 to 0.19 mg/kg/d). Main Outcome Measures Change in A1c, lipid, and transaminase levels after a mean ± standard deviation (SD) of 12 ± 0.2 months and 61 ± 39 months. Changes in liver histology, growth, and pubertal development throughout treatment. Results After 12 months, the A1c level (mean ± SD) decreased from 8.3% ± 2.4% to 6.5% ± 1.8%, and median triglyceride level decreased from 374 mg/dL [geometric mean (25th,75th percentile), 190, 1065] to 189 mg/dL (112, 334; P < 0.0001), despite decreased glucose- and lipid-lowering medications. The median [geometric mean (25th,75th percentile)] alanine aminotransferase level decreased from 73 U/L (45, 126) to 41 U/L (25, 59; P = 0.001), and that of aspartate aminotransferase decreased from 51 U/L (29, 90) to 26 U/L (18, 42; P = 0.0002). These improvements were maintained over long-term treatment. In 17 patients who underwent paired biopsies, the NAFLD activity score (mean ± SD) decreased from 4.5 ± 2.0 to 3.4 ± 2.0 after 3.3 ± 3.2 years of metreleptin therapy (P = 0.03). There were no clinically significant changes in growth or puberty. Conclusion Metreleptin lowered A1c and triglyceride levels, and improved biomarkers of NAFLD in pediatric patients with lipodystrophy. These improvements are likely to reduce the lifetime burden of disease.

[1]  J. Chan,et al.  Immunogenicity associated with metreleptin treatment in patients with obesity or lipodystrophy , 2016, Clinical endocrinology.

[2]  H. Kayserili,et al.  Natural History of Congenital Generalized Lipodystrophy: A Nationwide Study From Turkey. , 2016, The Journal of clinical endocrinology and metabolism.

[3]  E. Jaffe,et al.  Lymphoma in acquired generalized lipodystrophy , 2016, Leukemia & lymphoma.

[4]  P. Gorden,et al.  Metreleptin for injection to treat the complications of leptin deficiency in patients with congenital or acquired generalized lipodystrophy , 2016, Expert review of clinical pharmacology.

[5]  P. Gorden,et al.  Partial and generalized lipodystrophy: comparison of baseline characteristics and response to metreleptin. , 2015, The Journal of clinical endocrinology and metabolism.

[6]  K. Rother,et al.  Bone mineral content in patients with congenital generalized lipodystrophy is unaffected by metreleptin replacement therapy. , 2014, The Journal of clinical endocrinology and metabolism.

[7]  A. Testro,et al.  Post–Liver Transplant Leptin Results in Resolution of Severe Recurrence of Lipodystrophy‐Associated Nonalcoholic Steatohepatitis , 2013, American Journal of Transplantation.

[8]  K. Rother,et al.  Novel Forms of Lipodystrophy , 2013, Diabetes Care.

[9]  D. Kleiner,et al.  The liver diseases of lipodystrophy: the long-term effect of leptin treatment. , 2013, Journal of hepatology.

[10]  M. Tena-Sempere,et al.  Metabolic control of puberty: Roles of leptin and kisspeptins , 2013, Hormones and Behavior.

[11]  J. Chan,et al.  The clinical approach to the detection of lipodystrophy - an AACE consensus statement. , 2013, Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists.

[12]  P. Gorden,et al.  Consequences of Stopping and Restarting Leptin in an Adolescent with Lipodystrophy , 2012, Hormone Research in Paediatrics.

[13]  J. Chan,et al.  Clinical effects of long-term metreleptin treatment in patients with lipodystrophy. , 2011, Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists.

[14]  A. Garg.  Lipodystrophies: Genetic and Acquired Body Fat Disorders , 2011 .

[15]  J. Chan,et al.  Rationale for leptin-replacement therapy for severe lipodystrophy. , 2010, Endocrine Practice.

[16]  T. Kusakabe,et al.  Efficacy and safety of leptin-replacement therapy and possible mechanisms of leptin actions in patients with generalized lipodystrophy. , 2007, The Journal of clinical endocrinology and metabolism.

[17]  P. Gorden,et al.  Long-term efficacy of leptin replacement in patients with generalized lipodystrophy. , 2005, Diabetes.

[18]  O. Cummings,et al.  Design and validation of a histological scoring system for nonalcoholic fatty liver disease , 2005, Hepatology.

[19]  D. Kleiner,et al.  Leptin reverses nonalcoholic steatohepatitis in patients with severe lipodystrophy , 2005, Hepatology.

[20]  A. Kirk,et al.  Successful Renal Transplantation in a Patient with Congenital Generalized Lipodystrophy: A Case Report , 2004, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[21]  A. Garg,et al.  Clinical Features and Metabolic and Autoimmune Derangements in Acquired Partial Lipodystrophy: Report of 35 Cases and Review of the Literature , 2004, Medicine.

[22]  S. O’Rahilly,et al.  Genotype-phenotype relationships in Berardinelli-Seip congenital lipodystrophy , 2002, Journal of medical genetics.

[23]  K. Petersen,et al.  Leptin reverses insulin resistance and hepatic steatosis in patients with severe lipodystrophy. , 2002, The Journal of clinical investigation.

[24]  M. Reitman,et al.  Leptin-replacement therapy for lipodystrophy. , 2002, The New England journal of medicine.

[25]  R. Gilroy,et al.  LIPOATROPHIC DIABETES AND END-STAGE LIVER DISEASE SECONDARY TO NONALCOHOLIC STEATOHEPATITIS WITH RECURRENCE AFTER LIVER TRANSPLANTATION , 2001, Transplantation.

[26]  A. Garg.  Gender differences in the prevalence of metabolic complications in familial partial lipodystrophy (Dunnigan variety). , 2000 .

[27]  W. Greulich,et al.  Radiographic Atlas of Skeletal Development of the Hand and Wrist , 1999 .

[28]  R. Scully,et al.  Case records of the Massachusetts General Hospital. Weekly clinicopathological exercises. , 1976, The New England journal of medicine.

[29]  Ronald A. Arky,et al.  Case 1-1975 , 1975 .

[30]  P. Gorden,et al.  Efficacy of leptin therapy in the different forms of human lipodystrophy , 2009, Diabetologia.

[31]  D. Kleiner,et al.  Type 1 diabetes associated with acquired generalized lipodystrophy and insulin resistance: the effect of long-term leptin therapy. , 2008, The Journal of clinical endocrinology and metabolism.

[32]  S. O’Rahilly,et al.  Phenotypic and genetic heterogeneity in congenital generalized lipodystrophy. , 2003, The Journal of clinical endocrinology and metabolism.

[33]  Lester R Curtin,et al.  Centers for Disease Control and Prevention 2000 growth charts for the United States: improvements to the 1977 National Center for Health Statistics version. , 2002, Pediatrics.

[34]  Case records of the Massachusetts General Hospital. Weekly clinicopathological exercises. Case 1-1975. , 1975, The New England journal of medicine.